New Elite Feature: Screen & Chart at the same time

Gyre Therapeutics Inc.

Contributing Author

Recent Articles by Gyre Therapeutics Inc.

May-12	Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment GYRE GlobeNewswire
May-07	Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update GYRE -12.06% GlobeNewswire
May-04	Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical Company GYRE GlobeNewswire
Mar-17	Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment GYRE GlobeNewswire
Mar-12	Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update GYRE -6.30% GlobeNewswire
Jan-05	Gyre Therapeutics Announces Alignment with China's CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting GYRE +16.30% GlobeNewswire
Nov-07	Gyre Therapeutics Reports Third Quarter 2025 and Year-to-Date Financial Results and Provides Business Update GYRE GlobeNewswire
Oct-15	Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis GYRE +10.74% GlobeNewswire
Oct-14	Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD-The Liver Meeting 2025 GYRE GlobeNewswire
Sep-05	Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference GYRE GlobeNewswire
Aug-22	Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors GYRE +8.34% GlobeNewswire
Aug-11	Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update GYRE +6.93% GYRE GlobeNewswire
Jun-10	Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China GYRE +5.88% GlobeNewswire
May-29	Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares GYRE GlobeNewswire
May-22	Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock GYRE -22.57% GlobeNewswire
May-22	Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock GYRE -22.57% GYRE +8.10% GlobeNewswire
May-22	Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China GYRE -22.57% GYRE +8.10% GlobeNewswire
May-09	Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update GYRE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)